Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Other Operating Expenses (2016 - 2025)

Sonoma Pharmaceuticals has reported Other Operating Expenses over the past 11 years, most recently at -$271000.0 for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 341.96% year-over-year to -$271000.0; the TTM value through Dec 2025 reached -$684000.0, down 194.34%, while the annual FY2025 figure was $803000.0, 343.33% up from the prior year.
  • Other Operating Expenses for Q4 2025 was -$271000.0 at Sonoma Pharmaceuticals, up from -$394000.0 in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $387000.0 in Q3 2024 and troughed at -$731000.0 in Q1 2021.
  • A 5-year average of -$119631.6 and a median of -$90000.0 in 2023 define the central range for Other Operating Expenses.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 530.0% in 2024 and later tumbled 341.96% in 2025.
  • Year by year, Other Operating Expenses stood at $150000.0 in 2021, then crashed by 147.33% to -$71000.0 in 2022, then dropped by 11.27% to -$79000.0 in 2023, then surged by 241.77% to $112000.0 in 2024, then crashed by 341.96% to -$271000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for SNOA at -$271000.0 in Q4 2025, -$394000.0 in Q3 2025, and -$147000.0 in Q2 2025.